BACKGROUND: Epidermal growth factor receptor (EGFR) overexpression is associated with several key features of cancer development and growth. Therefore, EGFR is a very promising biological target for tumor diagnosis and anticancer therapy. Characterization of EGFR expression is important for clinicians to select patients for EGFR-targeted therapy and evaluate therapeutic effects. PURPOSE: To investigate whether near-infrared (NIR) fluorescent dye Cy5.5-labeled anti-EGFR monoclonal antibody Erbitux can characterize EGFR expression level in MDA-MB-231 and MCF-7 breast cancer xenografts using an in vivo NIR imaging method. MATERIAL AND METHODS: A fluorochrome probe was designed by coupling Cy5.5 to Erbitux through acidylation, and the fluorescence property of the Erbitux-Cy5.5 conjugate was characterized by fluorospectroscopy. Flow cytometry and laser confocal microscopy were used to test the EGFR specificity of the antibody probe in vitro. Erbitux-Cy5.5 was also injected intravenously into immune-deficient mice bearing MDA-MB-231 or MCF-7 tumors. Whole-body and region-of-interest fluorescence images were acquired and analyzed. The EGFR expression was also analyzed and confirmed by immunohistochemical assay. RESULTS: The maximum excitation/emission wavelength for the Erbitux-Cy5.5 probe was 674/697 nm, similar to that of free Cy5.5 (674/712 nm). Confocal microscopy confirmed receptor-specific uptake in MDA-MB-231 and MCF-7 cells. In flow cytometry probe specificity assay, Erbitux-Cy5.5 showed a 9.32-fold higher affinity for MDA-MB-231 than MCF-7 cells. In vivo NIR imaging also indicated specific uptake in EGFR-positive tumors. Probe uptake rate and maximum intake dose in MDA-MB-231 were significantly higher than those in MCF-7 xenografts (P < 0.001). Immunohistochemical staining confirmed the in vivo imaging results, showing differentiated EGFR expression in MDA-MB-231 (+ + +) and MCF-7 (+) tumor tissues. CONCLUSION: Erbitux-Cy5.5 may be used as a specific NIR contrast agent for the noninvasive characterization of EGFR expression level in breast cancer xenografts.
BACKGROUND:Epidermal growth factor receptor (EGFR) overexpression is associated with several key features of cancer development and growth. Therefore, EGFR is a very promising biological target for tumor diagnosis and anticancer therapy. Characterization of EGFR expression is important for clinicians to select patients for EGFR-targeted therapy and evaluate therapeutic effects. PURPOSE: To investigate whether near-infrared (NIR) fluorescent dye Cy5.5-labeled anti-EGFR monoclonal antibody Erbitux can characterize EGFR expression level in MDA-MB-231 and MCF-7 breast cancer xenografts using an in vivo NIR imaging method. MATERIAL AND METHODS: A fluorochrome probe was designed by coupling Cy5.5 to Erbitux through acidylation, and the fluorescence property of the Erbitux-Cy5.5 conjugate was characterized by fluorospectroscopy. Flow cytometry and laser confocal microscopy were used to test the EGFR specificity of the antibody probe in vitro. Erbitux-Cy5.5 was also injected intravenously into immune-deficient mice bearing MDA-MB-231 or MCF-7 tumors. Whole-body and region-of-interest fluorescence images were acquired and analyzed. The EGFR expression was also analyzed and confirmed by immunohistochemical assay. RESULTS: The maximum excitation/emission wavelength for the Erbitux-Cy5.5 probe was 674/697 nm, similar to that of free Cy5.5 (674/712 nm). Confocal microscopy confirmed receptor-specific uptake in MDA-MB-231 and MCF-7 cells. In flow cytometry probe specificity assay, Erbitux-Cy5.5 showed a 9.32-fold higher affinity for MDA-MB-231 than MCF-7 cells. In vivo NIR imaging also indicated specific uptake in EGFR-positive tumors. Probe uptake rate and maximum intake dose in MDA-MB-231 were significantly higher than those in MCF-7 xenografts (P < 0.001). Immunohistochemical staining confirmed the in vivo imaging results, showing differentiated EGFR expression in MDA-MB-231 (+ + +) and MCF-7 (+) tumor tissues. CONCLUSION:Erbitux-Cy5.5 may be used as a specific NIR contrast agent for the noninvasive characterization of EGFR expression level in breast cancer xenografts.
Authors: B C Jang; T Sanchez; H J Schaefers; O C Trifan; C H Liu; C Creminon; C K Huang; T Hla Journal: J Biol Chem Date: 2000-12-15 Impact factor: 5.157
Authors: Michael S Gee; Rabi Upadhyay; Henry Bergquist; Herlen Alencar; Fred Reynolds; Marco Maricevich; Ralph Weissleder; Lee Josephson; Umar Mahmood Journal: Radiology Date: 2008-07-22 Impact factor: 11.105
Authors: Kimberley S Samkoe; Jason R Gunn; Kayla Marra; Sally M Hull; Karen L Moodie; Joachim Feldwisch; Theresa V Strong; Daniel R Draney; P Jack Hoopes; David W Roberts; Keith Paulsen; Brian W Pogue Journal: Mol Imaging Biol Date: 2017-08 Impact factor: 3.488
Authors: Marleen van Oosten; Lucia Ma Crane; Joost Bart; Fijs W van Leeuwen; Gooitzen M van Dam Journal: Transl Oncol Date: 2011-04-01 Impact factor: 4.243
Authors: Paul L Chariou; Karin L Lee; Amy M Wen; Neetu M Gulati; Phoebe L Stewart; Nicole F Steinmetz Journal: Bioconjug Chem Date: 2015-02-05 Impact factor: 4.774
Authors: Brian W Pogue; Keith D Paulsen; Sally M Hull; Kimberly S Samkoe; Jason Gunn; Jack Hoopes; David W Roberts; Theresa V Strong; Daniel Draney; Joachim Feldwisch Journal: Proc SPIE Int Soc Opt Eng Date: 2015-03-04